Review article · 2025 · Open access
Strategic and Chemical Advances in Antibody–Drug Conjugates
Pharmaceutics, 17(9), 1164 · Published 5 September 2025 · DOI 10.3390/pharmaceutics17091164
In brief
“Strategic and Chemical Advances in Antibody–Drug Conjugates” is a 2025 review article by Ibrahim A. Alradwan and 9 co-authors, published in Pharmaceutics. OpenAlex counts 48 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Pharmaceutics.
- Citations
- 48
- Most cited in
- 2026 (45)
- Field-weighted impact
- 3.10
- References
- 178
- Authors
- 10
Abstract
Antibody-drug conjugates (ADCs) are a rapidly advancing class of targeted cancer therapeutics that couple the antigen specificity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule drugs. In their core design, a tumor-targeting antibody is covalently linked to a cytotoxic payload via a chemical linker, enabling the selective delivery of highly potent agents to malignant cells while sparing normal tissues, thereby improving the therapeutic index. Humanized and fully human immunoglobulin G1(IgG1) antibodies are the most common ADC backbones due to their stability in systemic circulation, robust Fcγ receptor engagement for immune effector functions, and reduced immunogenicity. Antibody selection requires balancing tumor specificity, internalization rate, and binding affinity to avoid barriers to tissue penetration, such as the binding-site barrier effect, while emerging designs exploit tumor-specific antigen variants or unique post-translational modifications to further enhance selectivity. Advances in antibody engineering, linker chemistry, and payload innovation have reinforced the clinical success of ADCs, with more than a dozen agents FDA approved for hematologic malignancies and solid tumors and over 200 in active clinical trials. This review critically examines established and emerging conjugation strategies, including lysine- and cysteine-based chemistries, enzymatic tagging, glycan remodeling, non-canonical amino acid incorporation, and affinity peptide-mediated methods, and discusses how conjugation site, drug-to-antibody ratio (DAR) control, and linker stability influence pharmacokinetics, efficacy, and safety. Innovations in site-specific conjugation have improved ADC homogeneity, stability, and clinical predictability, though challenges in large-scale manufacturing and regulatory harmonization remain. Furthermore, novel ADC architectures such as bispecific ADCs, conditionally active (probody) ADCs, immune-stimulating ADCs, protein-degrader ADCs, and dual-payload designs are being developed to address tumor heterogeneity, drug resistance, and off-target toxicity. By integrating mechanistic insights, preclinical and clinical data, and recent technological advances, this work highlights current progress and future directions for next-generation ADCs aimed at achieving superior efficacy, safety, and patient outcomes, especially in treating refractory cancers.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Alradwan, I. A., Alnefaie, M. K., AL Fayez, N., Aodah, A. H., Majrashi, M. A., Alturki, M., Fallatah, M., Almughem, F. A., Tawfik, E. A., & Alshehri, A. A. (2025). Strategic and Chemical Advances in Antibody–Drug Conjugates. Pharmaceutics, 17(9), 1164. https://doi.org/10.3390/pharmaceutics17091164
MLA 9
Alradwan, Ibrahim A., et al. “Strategic and Chemical Advances in Antibody–Drug Conjugates.” Pharmaceutics, vol. 17, no. 9, 2025, p. 1164. https://doi.org/10.3390/pharmaceutics17091164.
Chicago
Alradwan, Ibrahim A., Meshal K. Alnefaie, Nojoud AL Fayez, Alhassan H. Aodah, Majed A. Majrashi, Meshael Alturki, Mohannad Fallatah, Fahad A. Almughem, Essam A. Tawfik, and Abdullah Awad Alshehri. 2025. “Strategic and Chemical Advances in Antibody–Drug Conjugates.” Pharmaceutics 17 (9): 1164. https://doi.org/10.3390/pharmaceutics17091164.
Harvard
Alradwan, I. A. et al. (2025) ‘Strategic and Chemical Advances in Antibody–Drug Conjugates’, Pharmaceutics, 17(9), p. 1164. doi:10.3390/pharmaceutics17091164.
IEEE
I. A. Alradwan et al., “Strategic and Chemical Advances in Antibody–Drug Conjugates,” Pharmaceutics, vol. 17, no. 9, p. 1164, 2025, doi: 10.3390/pharmaceutics17091164.
BibTeX
@article{alradwan2025strategic,
title = {{Strategic and Chemical Advances in Antibody–Drug Conjugates}},
author = {Alradwan, Ibrahim A. and Alnefaie, Meshal K. and AL Fayez, Nojoud and Aodah, Alhassan H. and Majrashi, Majed A. and Alturki, Meshael and Fallatah, Mohannad and Almughem, Fahad A. and Tawfik, Essam A. and Alshehri, Abdullah Awad},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {9},
pages = {1164},
doi = {10.3390/pharmaceutics17091164},
url = {https://doi.org/10.3390/pharmaceutics17091164}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 1 | |
| 2025 | 2 | |
| 2026 | 45 |
Its field-weighted citation impact is 3.10: it has been cited 3.10 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- antibody-drug conjugates
- linker chemistry
- site-specific conjugation
- drug-to-antibody ratio
- IgG1 antibodies
- antibody engineering
- glycan remodeling
- non-canonical amino acid incorporation
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Alradwan, I. A., Alnefaie, M. K., AL Fayez, N., Aodah, A. H., Majrashi, M. A., Alturki, M., Fallatah, M., Almughem, F. A., Tawfik, E. A., & Alshehri, A. A. (2025). Strategic and Chemical Advances in Antibody–Drug Conjugates. Pharmaceutics, 17(9), 1164. https://doi.org/10.3390/pharmaceutics17091164
How many times has this paper been cited?
48 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Pharmaceutics: sign in and open the PDF from this page.
Who wrote this paper?
Ibrahim A. Alradwan, Meshal K. Alnefaie, Nojoud AL Fayez, Alhassan H. Aodah, Majed A. Majrashi, Meshael Alturki, Mohannad Fallatah, Fahad A. Almughem, Essam A. Tawfik, Abdullah Awad Alshehri.
What is the DOI of this paper?
10.3390/pharmaceutics17091164, permanently at https://doi.org/10.3390/pharmaceutics17091164. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.